Elevance Health Receives $387.40 Consensus Target Price from Analysts

The health insurance provider's stock is rated 'Moderate Buy' by 22 research firms.

Mar. 23, 2026 at 7:34am

Got story updates? Submit your updates here. ›

Elevance Health, Inc. (NYSE:ELV) has received a 'Moderate Buy' consensus recommendation from 22 research firms covering the company, with an average 12-month price target of $387.40. The company's stock has been rated with one sell recommendation, nine hold recommendations, and twelve buy recommendations.

Why it matters

As one of the largest health insurance providers in the U.S., Elevance Health's financial performance and outlook are closely watched by investors and analysts. The consensus target price and rating provide insight into how the investment community views the company's prospects.

The details

The analysts' consensus target price of $387.40 represents potential upside from the company's current stock price. However, some firms have lowered their price targets, with Mizuho reducing its target from $413 to $350 and Truist Financial dropping its target from $400 to $390. The analysts' ratings and price targets reflect their assessments of Elevance Health's business fundamentals, competitive position, and growth potential.

  • Elevance Health last reported quarterly earnings on January 28, 2026.
  • The company has set its fiscal year 2026 earnings per share guidance at $25.50 or more.

The players

Elevance Health, Inc.

A large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc. to Elevance Health in 2022.

Gail Boudreaux

The chief executive officer and president of Elevance Health, leading the company's strategic focus on integrated health care and benefit delivery.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.